Article

Gene-expression profiles and age of donor kidney biopsies obtained before transplantation distinguish medium term graft function.

Department of Nephrology, KH Elisabethinen Linz, and Medical University of Vienna, Vienna, Austria.
Transplantation (Impact Factor: 3.78). 04/2007; 83(8):1048-54. DOI: 10.1097/01.tp.0000259960.56786.ec
Source: PubMed

ABSTRACT Donor factors such as age profoundly influence long-term graft function after cadaveric renal transplantation, but the molecular signature of these aspects in the allograft remains unknown.
We analyzed the genome-wide gene expression signature of donor kidney biopsies of different ages obtained before transplantation. Subsequent analysis compared expression profiles from allografts with excellent function versus impaired function at 1 yr after engraftment. Differential expression profiles were analyzed on the level of molecular function and biologic role, as well as by analysis of co-regulation through transcription factors, regulatory networks, and protein-protein interaction data utilizing extended bioinformatics.
The 15 subjects with excellent transplant function defined as calculated GFR>or=45 mL/min/1.73 m2 at 1 yr exhibited a distinctly different gene expression profile than the matched 16 subjects with impaired function defined as calculated GFR<45 mL/min/1.73 m2. Donor kidneys from recipients with impaired allograft function showed activation of genes mainly belonging to the functional classes of immunity, signal transduction, and oxidative stress response. Two-thirds of these genes exhibited at least one protein interacting partner, suggesting choreographed intracellular events differentiating the two recipient groups. However, donor age may have confounded some of the associations found between gene profiles and graft function.
In summary, a distinctive gene expression profile in the donor kidney at transplantation together with donor age predicts medium term allograft function in recipients of cadaveric allografts.

0 Followers
 · 
80 Views
  • [Show abstract] [Hide abstract]
    ABSTRACT: Die perkutane Nierenbiopsie stellt derzeit den Goldstandard in der Diagnostik der meisten primären und sekundären Nierenerkrankungen dar. Sie dient der Identifikation und Klassifikation renaler Erkrankungen und ist die Grundlage für die Durchführung standardisierter Therapiekonzepte. Wie bei jeder anderen diagnostischen Technik hängt die Güte der ableitbaren Information von der vorhandenen Erfahrung und einer standardisierten Durchführung ab. Für die Nierenbiopsie sind dies v. a. die Gewinnung und adäquate Aufarbeitung von repräsentativem Nierengewebe.
    Der Nephrologe 05/2008; 3(3).
  • [Show abstract] [Hide abstract]
    ABSTRACT: Zusammenfassung Die perkutane Nierenbiopsie stellt derzeit den Goldstandard in der Diagnostik der meisten primären und sekundären Nierenerkrankungen dar. Sie dient der Identifikation und Klassifikation renaler Erkrankungen und ist die Grundlage für die Durchführung standardisierter Therapiekonzepte. Wie bei jeder anderen diagnostischen Technik hängt die Güte der ableitbaren Informationen von der vorhandenen Erfahrung und einer standardisierten Durchführung ab. Für die Nierenbiopsie sind dies v. a. die Gewinnung und adäquate Aufarbeitung von repräsentativem Nierengewebe. Die hierfür notwendigen Vorgehensweisen werden im vorliegenden Artikel genauer dargestellt und diskutiert.
    Der Pathologe 11/2011; DOI:10.1007/s00292-011-1484-5 · 0.64 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: Renal transplantation represents the most favorable treatment for patients with advanced renal failure and it is followed, in most cases, by a significant enhancement in patients' quality of life. Significant improvements in one-year renal allograft and patients' survival rates have been achieved over the last 10 years primarily as a result of newer immunosuppressive regimens. Despite these notable achievements in the short-term outcome, long-term graft function and survival rates remain less than optimal. Death with a functioning graft and chronic allograft dysfunction result in an annual rate of 3%-5%. In this context, drug toxicity and long-term chronic adverse effects of immunosuppressive medications have a pivotal role. Unfortunately, at the moment, except for the evaluation of trough drug levels, no clinically useful tools are available to correctly manage immunosuppressive therapy. The proper use of these drugs could potentiate therapeutic effects minimizing adverse drug reactions. For this purpose, in the future, "omics" techniques could represent powerful tools that may be employed in clinical practice to routinely aid the personalization of drug treatment according to each patient's genetic makeup. However, it is unquestionable that additional studies and technological advances are needed to standardize and simplify these methodologies.
    International Journal of Molecular Sciences 02/2015; 16(2):4281-4305. DOI:10.3390/ijms16024281 · 2.34 Impact Factor